Travere Therapeutics Inc
NASDAQ:TVTX

Watchlist Manager
Travere Therapeutics Inc Logo
Travere Therapeutics Inc
NASDAQ:TVTX
Watchlist
Price: 18.25 USD -0.82% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Travere Therapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one TVTX stock under the Base Case scenario is 21.77 USD. Compared to the current market price of 18.25 USD, Travere Therapeutics Inc is Undervalued by 16%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TVTX Intrinsic Value
21.77 USD
Undervaluation 16%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Travere Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TVTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TVTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Travere Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Travere Therapeutics Inc

Provide an overview of the primary business activities
of Travere Therapeutics Inc.

What unique competitive advantages
does Travere Therapeutics Inc hold over its rivals?

What risks and challenges
does Travere Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Travere Therapeutics Inc recently?

Summarize the latest earnings call
of Travere Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Travere Therapeutics Inc.

Provide P/S
for Travere Therapeutics Inc.

Provide P/E
for Travere Therapeutics Inc.

Provide P/OCF
for Travere Therapeutics Inc.

Provide P/FCFE
for Travere Therapeutics Inc.

Provide P/B
for Travere Therapeutics Inc.

Provide EV/S
for Travere Therapeutics Inc.

Provide EV/GP
for Travere Therapeutics Inc.

Provide EV/EBITDA
for Travere Therapeutics Inc.

Provide EV/EBIT
for Travere Therapeutics Inc.

Provide EV/OCF
for Travere Therapeutics Inc.

Provide EV/FCFF
for Travere Therapeutics Inc.

Provide EV/IC
for Travere Therapeutics Inc.

Show me price targets
for Travere Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Travere Therapeutics Inc?

How accurate were the past Revenue estimates
for Travere Therapeutics Inc?

What are the Net Income projections
for Travere Therapeutics Inc?

How accurate were the past Net Income estimates
for Travere Therapeutics Inc?

What are the EPS projections
for Travere Therapeutics Inc?

How accurate were the past EPS estimates
for Travere Therapeutics Inc?

What are the EBIT projections
for Travere Therapeutics Inc?

How accurate were the past EBIT estimates
for Travere Therapeutics Inc?

Compare the revenue forecasts
for Travere Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Travere Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Travere Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Travere Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Travere Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Travere Therapeutics Inc with its peers.

Analyze the financial leverage
of Travere Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Travere Therapeutics Inc.

Provide ROE
for Travere Therapeutics Inc.

Provide ROA
for Travere Therapeutics Inc.

Provide ROIC
for Travere Therapeutics Inc.

Provide ROCE
for Travere Therapeutics Inc.

Provide Gross Margin
for Travere Therapeutics Inc.

Provide Operating Margin
for Travere Therapeutics Inc.

Provide Net Margin
for Travere Therapeutics Inc.

Provide FCF Margin
for Travere Therapeutics Inc.

Show all solvency ratios
for Travere Therapeutics Inc.

Provide D/E Ratio
for Travere Therapeutics Inc.

Provide D/A Ratio
for Travere Therapeutics Inc.

Provide Interest Coverage Ratio
for Travere Therapeutics Inc.

Provide Altman Z-Score Ratio
for Travere Therapeutics Inc.

Provide Quick Ratio
for Travere Therapeutics Inc.

Provide Current Ratio
for Travere Therapeutics Inc.

Provide Cash Ratio
for Travere Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Travere Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Travere Therapeutics Inc?

What is the current Free Cash Flow
of Travere Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Travere Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Travere Therapeutics Inc

Current Assets 324.7m
Cash & Short-Term Investments 277.4m
Receivables 25.2m
Other Current Assets 22.1m
Non-Current Assets 179.7m
PP&E 21.8m
Intangibles 104.2m
Other Non-Current Assets 53.6m
Current Liabilities 190m
Accounts Payable 23.2m
Accrued Liabilities 72.1m
Other Current Liabilities 94.7m
Non-Current Liabilities 344.8m
Long-Term Debt 310m
Other Non-Current Liabilities 34.9m
Efficiency

Earnings Waterfall
Travere Therapeutics Inc

Revenue
203.4m USD
Cost of Revenue
-9.8m USD
Gross Profit
193.7m USD
Operating Expenses
-473.4m USD
Operating Income
-279.7m USD
Other Expenses
-71.8m USD
Net Income
-351.5m USD

Free Cash Flow Analysis
Travere Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

TVTX Profitability Score
Profitability Due Diligence

Travere Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Negative 3-Years Revenue Growth
23/100
Profitability
Score

Travere Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

TVTX Solvency Score
Solvency Due Diligence

Travere Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
50/100
Solvency
Score

Travere Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TVTX Price Targets Summary
Travere Therapeutics Inc

Wall Street analysts forecast TVTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TVTX is 27.48 USD with a low forecast of 15.15 USD and a high forecast of 44.1 USD.

Lowest
Price Target
15.15 USD
17% Downside
Average
Price Target
27.48 USD
51% Upside
Highest
Price Target
44.1 USD
142% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TVTX?

Click here to dive deeper.

Dividends

Travere Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for TVTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

TVTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

TVTX News

Other Videos

Profile

Travere Therapeutics Inc Logo
Travere Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.4B USD

Dividend Yield

0%

Description

Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 310 full-time employees. The company went IPO on 2003-07-23. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its products include Chenodal (chenodiol tablets), Cholbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The firm's clinical program Sparsentan (RE-021), is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker.

Contact

CALIFORNIA
San Diego
3611 Valley Centre Dr, Suite 300
+18889697879.0
travere.com

IPO

2003-07-23

Employees

310

Officers

President, CEO & Director
Dr. Eric M. Dube Ph.D.
Chief Financial Officer
Mr. Christopher Cline C.F.A.
Senior VP, General Counsel & Corporate Secretary
Ms. Elizabeth E. Reed J.D.
Senior VP and Head of Research & Development
Dr. William E. Rote Ph.D.
Chief Commercial Officer
Mr. Peter Heerma
SVP, Corporate Controller & Chief Accounting Officer
Ms. Sandra Calvin
Show More
Vice President of Corporate Communications & Investor Relations
Ms. Nivi Nehra
Senior Vice President of Human Resources
Ms. Angela Giannantonio
Chief Business Officer
Mr. Casey Logan
Chief Medical Officer
Dr. Jula Inrig M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one TVTX stock?

The intrinsic value of one TVTX stock under the Base Case scenario is 21.77 USD.

Is TVTX stock undervalued or overvalued?

Compared to the current market price of 18.25 USD, Travere Therapeutics Inc is Undervalued by 16%.

Back to Top